-
Your prediction
Pros and Cons of Advanced Proteome Therapeutics in the next few years
Pros
Cons
Performance of Advanced Proteome Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Advanced Proteome Therapeutics | - | - | - | - | - | - | - |
| Satellos Bioscience Inc. | -1.490% | -6.573% | -9.545% | -30.783% | -28.929% | 156.113% | - |
| Vaxart Inc. | 2.570% | -0.214% | -2.376% | -46.114% | -58.546% | -72.688% | -95.264% |
| Larimar Therapeutics Inc. | -1.380% | -15.882% | 0.000% | -27.041% | -23.118% | -30.918% | -82.540% |
News
If You'd Invested $10,000 in AMD 10 Years Ago, Here's How Much You'd Have Today
A decade ago, Advanced Micro Devices (NASDAQ: AMD) was in a difficult position. Revenue fell 28% in 2015, primarily due to declining processor sales, and the company posted a net loss of $660
AMD Shared Crucial Information About the AI Market
In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other AI stocks. To learn more, check out the short video, consider subscribing, and click the special
Nvidia vs AMD: Which AI Chipmaker Will Lead the Next Decade of Compute?
Nvidia (NASDAQ: NVDA) has been the "go-to" source for artificial intelligence (AI) chips since the start of the AI boom, and this is thanks to two things: the company's first-to-market advantage and


